Literature DB >> 17881441

Humanized NOD/SCID/IL2Rgamma(null) mice transplanted with hematopoietic stem cells under nonmyeloablative conditions show prolonged life spans and allow detailed analysis of human immunodeficiency virus type 1 pathogenesis.

Satoru Watanabe1, Shinrai Ohta, Misako Yajima, Kazuo Terashima, Mamoru Ito, Hideo Mugishima, Shigeyoshi Fujiwara, Kazufumi Shimizu, Mitsuo Honda, Norio Shimizu, Naoki Yamamoto.   

Abstract

In a previous study, we demonstrated that humanized NOD/SCID/IL2Rgamma(null) (hNOG) mice constructed with human hematopoietic stem cells (HSCs) allow efficient human immunodeficiency virus type 1 (HIV-1) infection. However, HIV-1 infection could be monitored for only 43 days in the animals due to their short life spans. By transplanting HSCs without any myeloablation methods, the mice successfully survived longer than 300 days with stable engraftment of human cells. The mice showed high viremia state for more than the 3 months examined, with systemic HIV-1 infection and gradual decrease of CD4+ T cells analogous to that in humans. These capacities of the hNOG mice are very attractive for modeling mechanisms of AIDS progression and therapeutic strategy.

Entities:  

Mesh:

Year:  2007        PMID: 17881441      PMCID: PMC2169100          DOI: 10.1128/JVI.01353-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/gammacnull mice model.

Authors:  Hidefumi Hiramatsu; Ryuta Nishikomori; Toshio Heike; Mamoru Ito; Kimio Kobayashi; Kenji Katamura; Tatsutoshi Nakahata
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

2.  beta2 microglobulin-deficient (B2m(null)) NOD/SCID mice are excellent recipients for studying human stem cell function.

Authors:  O Kollet; A Peled; T Byk; H Ben-Hur; D Greiner; L Shultz; T Lapidot
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

3.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

Authors:  Mamoru Ito; Hidefumi Hiramatsu; Kimio Kobayashi; Kazutomo Suzue; Mariko Kawahata; Kyoji Hioki; Yoshito Ueyama; Yoshio Koyanagi; Kazuo Sugamura; Kohichiro Tsuji; Toshio Heike; Tatsutoshi Nakahata
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

4.  HIV-1 infection and pathogenesis in a novel humanized mouse model.

Authors:  Liguo Zhang; Grigoriy I Kovalev; Lishan Su
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

5.  Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.

Authors:  M Tersmette; R A Gruters; F de Wolf; R E de Goede; J M Lange; P T Schellekens; J Goudsmit; H G Huisman; F Miedema
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

6.  Functional human T lymphocyte development from cord blood CD34+ cells in nonobese diabetic/Shi-scid, IL-2 receptor gamma null mice.

Authors:  Takashi Yahata; Kiyoshi Ando; Yoshihiko Nakamura; Yoshito Ueyama; Kazuo Shimamura; Norikazu Tamaoki; Shunichi Kato; Tomomitsu Hotta
Journal:  J Immunol       Date:  2002-07-01       Impact factor: 5.422

7.  Functional CD5+ B cells develop predominantly in the spleen of NOD/SCID/gammac(null) (NOG) mice transplanted either with human umbilical cord blood, bone marrow, or mobilized peripheral blood CD34+ cells.

Authors:  Takuya Matsumura; Yoshie Kametani; Kiyoshi Ando; Yasuyuki Hirano; Ikumi Katano; Ryoji Ito; Masashi Shiina; Hideo Tsukamoto; Yuki Saito; Yutaka Tokuda; Shunichi Kato; Mamoru Ito; Kazuo Motoyoshi; Sonoko Habu
Journal:  Exp Hematol       Date:  2003-09       Impact factor: 3.084

8.  Infection of the SCID-hu mouse by HIV-1.

Authors:  R Namikawa; H Kaneshima; M Lieberman; I L Weissman; J M McCune
Journal:  Science       Date:  1988-12-23       Impact factor: 47.728

9.  Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages.

Authors:  Tatsuhiko Igarashi; Olivia K Donau; Hiromi Imamichi; Marie-Jeanne Dumaurier; Reza Sadjadpour; Ronald J Plishka; Alicia Buckler-White; Charles Buckler; Anthony F Suffredini; H Clifford Lane; John P Moore; Malcolm A Martin
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans.

Authors:  T Igarashi; C R Brown; Y Endo; A Buckler-White; R Plishka; N Bischofberger; V Hirsch; M A Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

View more
  48 in total

1.  BLT-humanized C57BL/6 Rag2-/-γc-/-CD47-/- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection.

Authors:  Kerry J Lavender; Wendy W Pang; Ronald J Messer; Amanda K Duley; Brent Race; Katie Phillips; Dana Scott; Karin E Peterson; Charles K Chan; Ulf Dittmer; Timothy Dudek; Todd M Allen; Irving L Weissman; Kim J Hasenkrug
Journal:  Blood       Date:  2013-09-10       Impact factor: 22.113

2.  A mouse model for HIV-1 entry.

Authors:  John Pietzsch; Henning Gruell; Stylianos Bournazos; Bridget M Donovan; Florian Klein; Ron Diskin; Michael S Seaman; Pamela J Bjorkman; Jeffrey V Ravetch; Alexander Ploss; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-10       Impact factor: 11.205

3.  Production of bone marrow, liver, thymus (BLT) humanized mice on the C57BL/6 Rag2(-/-)γc(-/-)CD47(-/-) background.

Authors:  Kerry J Lavender; Ronald J Messer; Brent Race; Kim J Hasenkrug
Journal:  J Immunol Methods       Date:  2014-04-24       Impact factor: 2.303

4.  One-Year Observation of the SCID-Repopulating Cell Activities of Human Cord Blood-Derived CD34-Positive and -Negative Hematopoietic Stem Cells.

Authors:  Yoshikazu Matsuoka; Keisuke Sumide; Yoshiaki Sonoda
Journal:  Stem Cell Rev Rep       Date:  2019-06       Impact factor: 5.739

5.  Dysregulation of claudin-5 in HIV-induced interstitial pneumonitis and lung vascular injury. Protective role of peroxisome proliferator-activated receptor-γ.

Authors:  Hong Li; Sangya Singh; Raghava Potula; Yuri Persidsky; Georgette D Kanmogne
Journal:  Am J Respir Crit Care Med       Date:  2014-07-01       Impact factor: 21.405

Review 6.  Novel humanized murine models for HIV research.

Authors:  Paul W Denton; J Victor Garcia
Journal:  Curr HIV/AIDS Rep       Date:  2009-02       Impact factor: 5.071

7.  T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice.

Authors:  Priti Kumar; Hong-Seok Ban; Sang-Soo Kim; Haoquan Wu; Todd Pearson; Dale L Greiner; Amale Laouar; Jiahong Yao; Viraga Haridas; Katsuyoshi Habiro; Yong-Guang Yang; Ji-Hoon Jeong; Kuen-Yong Lee; Yong-Hee Kim; Sung Wan Kim; Matthias Peipp; Georg H Fey; N Manjunath; Leonard D Shultz; Sang-Kyung Lee; Premlata Shankar
Journal:  Cell       Date:  2008-08-07       Impact factor: 41.582

8.  Studies of lymphocyte reconstitution in a humanized mouse model reveal a requirement of T cells for human B cell maturation.

Authors:  Julie Lang; Margot Kelly; Brian M Freed; Martin D McCarter; Ross M Kedl; Raul M Torres; Roberta Pelanda
Journal:  J Immunol       Date:  2013-01-18       Impact factor: 5.422

Review 9.  The utilization of humanized mouse models for the study of human retroviral infections.

Authors:  Rachel Van Duyne; Caitlin Pedati; Irene Guendel; Lawrence Carpio; Kylene Kehn-Hall; Mohammed Saifuddin; Fatah Kashanchi
Journal:  Retrovirology       Date:  2009-08-12       Impact factor: 4.602

10.  Priming of protective T cell responses against virus-induced tumors in mice with human immune system components.

Authors:  Till Strowig; Cagan Gurer; Alexander Ploss; Yi-Fang Liu; Frida Arrey; Junji Sashihara; Gloria Koo; Charles M Rice; James W Young; Amy Chadburn; Jeffrey I Cohen; Christian Münz
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.